Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer.

Palazzo A, Dellapasqua S, Munzone E, Bagnardi V, Mazza M, Cancello G, Ghisini R, Iorfida M, Montagna E, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2018 Feb 2. pii: S1526-8209(17)30737-1. doi: 10.1016/j.clbc.2018.01.010. [Epub ahead of print]

PMID:
29486983
2.

Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes.

Montagna E, Pirola S, Maisonneuve P, De Roberto G, Cancello G, Palazzo A, Viale G, Colleoni M.

Clin Breast Cancer. 2018 Jun;18(3):e401-e405. doi: 10.1016/j.clbc.2017.07.003. Epub 2017 Jul 10.

PMID:
28778379
3.

Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.

Montagna E, Vingiani A, Maisonneuve P, Cancello G, Contaldo F, Pruneri G, Colleoni M.

Breast. 2017 Aug;34:83-88. doi: 10.1016/j.breast.2017.05.009. Epub 2017 May 23.

PMID:
28544923
4.

Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.

Montagna E, Palazzo A, Maisonneuve P, Cancello G, Iorfida M, Sciandivasci A, Esposito A, Cardillo A, Mazza M, Munzone E, Lai A, Goldhirsch A, Colleoni M.

Cancer Lett. 2017 Aug 1;400:276-281. doi: 10.1016/j.canlet.2017.01.027. Epub 2017 Jan 26.

PMID:
28131905
5.

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancello G, Munzone E, Gelber RD, Regan MM, Colleoni M.

Breast Cancer Res Treat. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2.

6.

Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.

Balduzzi A, Bagnardi V, Sandri MT, Dellapasqua S, Cardillo A, Montagna E, Cancello G, Iorfida M, Ghisini R, Viale G, Intra M, Luini A, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2015 Oct;15(5):e257-62. doi: 10.1016/j.clbc.2015.03.007. Epub 2015 Apr 30.

PMID:
26362840
7.

Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Cancello G, Palazzo A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Santillo B, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2015 Dec;15(6):440-7. doi: 10.1016/j.clbc.2015.07.003. Epub 2015 Jul 10.

PMID:
26255932
8.

Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.

Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, Sporchia A, Iorfida M, Viale G, Barberis M, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2015 Aug;15(4):259-65. doi: 10.1016/j.clbc.2015.03.002. Epub 2015 Mar 18.

PMID:
25933934
9.

Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.

Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, Balduzzi A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Casadio C, Sangalli C, Goldhirsch A, Colleoni M.

Ann Oncol. 2015 Feb;26(2):307-13. doi: 10.1093/annonc/mdu528. Epub 2014 Nov 19.

PMID:
25411418
10.

Metronomic therapy and breast cancer: a systematic review.

Montagna E, Cancello G, Dellapasqua S, Munzone E, Colleoni M.

Cancer Treat Rev. 2014 Sep;40(8):942-50. doi: 10.1016/j.ctrv.2014.06.002. Epub 2014 Jun 18. Review.

PMID:
24998489
11.

Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"?

Cancello G, Maisonneuve P, Mazza M, Montagna E, Rotmensz N, Viale G, Pruneri G, Veronesi P, Luini A, Gentilini O, Goldhirsch A, Colleoni M.

Breast. 2013 Dec;22(6):1046-51. doi: 10.1016/j.breast.2013.08.006. Epub 2013 Sep 30.

PMID:
24091127
12.

Treatment of breast cancer in young women: do we need more aggressive therapies?

Cancello G, Montagna E.

J Thorac Dis. 2013 Jun;5 Suppl 1:S47-54. doi: 10.3978/j.issn.2072-1439.2013.06.10.

13.

The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?

Montagna E, Cancello G, Colleoni M.

Cancer Treat Rev. 2013 Dec;39(8):886-90. doi: 10.1016/j.ctrv.2013.04.007. Epub 2013 May 29. Review.

PMID:
23725877
14.

Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.

Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, Galimberti V, Veronesi P, Luini A, Pruneri G, Bottiglieri L, Mastropasqua MG, Goldhirsch A, Viale G, Colleoni M.

Clin Breast Cancer. 2013 Feb;13(1):31-9. doi: 10.1016/j.clbc.2012.09.002. Epub 2012 Oct 24.

PMID:
23098574
15.

Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M.

Ann Oncol. 2013 Mar;24(3):661-8. doi: 10.1093/annonc/mds430. Epub 2012 Sep 28.

PMID:
23022996
16.

Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, Calleri A, Rampinelli C, Goldhirsch A, Bertolini F, Colleoni M.

Clin Breast Cancer. 2012 Jun;12(3):207-14. doi: 10.1016/j.clbc.2012.03.008. Epub 2012 Apr 20.

PMID:
22520733
17.

Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.

Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, Montagna E, Balduzzi A, Mancuso P, Luini A, Goldhirsch A, Colleoni M.

Breast. 2012 Jun;21(3):309-13. doi: 10.1016/j.breast.2012.01.015. Epub 2012 Feb 16.

PMID:
22341133
18.

Outcome of special types of luminal breast cancer.

Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, Intra M, Montagna E, Cancello G, Cardillo A, Mazza M, Perri G, Iorfida M, Pruneri G, Goldhirsch A, Viale G.

Ann Oncol. 2012 Jun;23(6):1428-36. doi: 10.1093/annonc/mdr461. Epub 2011 Oct 29.

PMID:
22039080
19.

Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Cancello G, Mazza M, Cardillo A, Ghisini R, Galimberti V, Veronesi P, Monti S, Luini A, Raviele PR, Mastropasqua MG, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2011 Oct;129(3):867-75. doi: 10.1007/s10549-011-1697-6. Epub 2011 Aug 6.

PMID:
21822638
20.

Breast cancer subtypes and outcome after local and regional relapse.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M.

Ann Oncol. 2012 Feb;23(2):324-31. doi: 10.1093/annonc/mdr129. Epub 2011 Apr 27.

PMID:
21525402
21.

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2011 Jun;127(3):713-20. doi: 10.1007/s10549-011-1465-7. Epub 2011 Mar 31.

PMID:
21452022
22.

Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.

Torrisi R, Cardillo A, Cancello G, Dellapasqua S, Balduzzi A, Ghisini R, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2010 Dec 1;10(6):483-8. doi: 10.3816/CBC.2010.n.064.

PMID:
21147693
23.

Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.

Torrisi R, Montagna E, Scarano E, Dellapasqua S, Cancello G, Iorfida M, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M.

Breast. 2011 Feb;20(1):34-8. doi: 10.1016/j.breast.2010.06.005. Epub 2010 Jul 16.

PMID:
20638282
24.

Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2010 Dec;124(3):689-99. doi: 10.1007/s10549-010-1027-4. Epub 2010 Jul 13.

PMID:
20625816
25.

Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M.

Ann Oncol. 2010 Oct;21(10):1974-81. doi: 10.1093/annonc/mdq072. Epub 2010 Mar 23.

PMID:
20332136
26.

Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.

Rocca A, Cancello G, Bagnardi V, Sandri MT, Torrisi R, Zorzino L, Viale G, Pietri E, Veronesi P, Dellapasqua S, Ferrucci F, Luini A, Johansson H, Ghisini R, Goldhirsch A, Colleoni M.

Anticancer Res. 2009 Dec;29(12):5111-9.

27.

Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.

Montagna E, Cancello G, Torrisi R, Rizzo S, Scarano E, Colleoni M.

Ann Oncol. 2010 Mar;21(3):667-8. doi: 10.1093/annonc/mdp563. Epub 2009 Dec 23. No abstract available.

PMID:
20032127
28.

Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure.

Montagna E, Viale G, Rotmensz N, Maisonneuve P, Galimberti V, Luini A, Intra M, Veronesi P, Mazzarol G, Pruneri G, Renne G, Torrisi R, Cardillo A, Cancello G, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2009 Nov;118(2):385-94. doi: 10.1007/s10549-009-0446-6. Epub 2009 Jun 27.

PMID:
19562480
29.

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.

Cancello G, Montagna E, D'Agostino D, Giuliano M, Giordano A, Di Lorenzo G, Plaitano M, De Placido S, De Laurentiis M.

Breast Cancer Res. 2008;10(4):R60. doi: 10.1186/bcr2119. Epub 2008 Jul 16.

30.

Biology, prognosis and response to therapy of breast carcinomas according to HER2 score.

Ménard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, Gloghini A, Scalone S, Querzoli P, Lunardi M, Molino A, Mandarà M, Mottolese M, Marandino F, Venturini M, Bighin C, Cancello G, Montagna E, Perrone F, De Matteis A, Sapino A, Donadio M, Battelli N, Santinelli A, Pavesi L, Lanza A, Zito FA, Labriola A, Aiello RA, Caruso M, Zanconati F, Mustacchi G, Barbareschi M, Frisinghelli M, Russo R, Carrillo G; OMERO Group.

Ann Oncol. 2008 Oct;19(10):1706-12. doi: 10.1093/annonc/mdn369. Epub 2008 Jun 9.

PMID:
18544559
31.

Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.

Montagna E, Cancello G, D'Agostino D, Lauria R, Forestieri V, Esposito A, Silvestro L, Accurso A, De Placido S, De Laurentiis M.

Cancer Chemother Pharmacol. 2009 Jan;63(2):275-80. doi: 10.1007/s00280-008-0737-3. Epub 2008 Apr 1.

PMID:
18379783
32.

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S.

J Clin Oncol. 2008 Jan 1;26(1):44-53. doi: 10.1200/JCO.2007.11.3787.

PMID:
18165639
33.

Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.

Di Lorenzo G, Autorino R, Perdonà S, De Laurentiis M, D'Armiento M, Cancello G, Mirone V, Imbimbo C, Longo N, Altieri V, Tortora G, Figg WD, De Placido S.

Eur Urol. 2007 Oct;52(4):1020-7. Epub 2007 Mar 7.

PMID:
17360103
34.

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S.

Clin Cancer Res. 2005 Jul 1;11(13):4741-8.

35.

Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.

De Laurentiis M, Cancello G, Zinno L, Montagna E, Malorni L, Esposito A, Pennacchio R, Silvestro L, Giuliano M, Giordano A, Caputo F, Accurso A, De Placido S.

Ann Oncol. 2005 May;16 Suppl 4:iv7-13. Review.

PMID:
15923434
36.

Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer.

Di Lorenzo G, Pizza C, Autorino R, De Laurentiis M, Marano O, D'Alessio A, Cancello G, Altieri V, Tortora G, Perdonà S, Bianco AR, De Placido S.

Eur Urol. 2004 Dec;46(6):712-6.

PMID:
15548437

Supplemental Content

Loading ...
Support Center